))
The Longevity Investors: Can We TRULY End Aging? The Longevity Moonshots Explained
Manage episode 506506916 series 3669813
A tartalmat a Julian Issa biztosítja. Az összes podcast-tartalmat, beleértve az epizódokat, grafikákat és podcast-leírásokat, közvetlenül a Julian Issa vagy a podcast platform partnere tölti fel és biztosítja. Ha úgy gondolja, hogy valaki az Ön engedélye nélkül használja fel a szerzői joggal védett művét, kövesse az itt leírt folyamatot https://hu.player.fm/legal.
Living to 120 is no longer science fiction. It’s quickly becoming one of the most ambitious investment frontiers of our time.
Join me at the Global Longevity Summit this October. Use code BEYONDTOMORROW for 10% off your ticket: https://informaconnect.com/global-longevity-summit/
In this Moonshot Special of Longevity Unpacked, I sit down with Will Harborne and Sebastian Brunemeier from LongGame Ventures. They’re not just talking about supplements or lifestyle hacks, they’re backing companies working on gene therapies, stem cell treatments, organ replacement, and even embryo selection.
We also dig into why longevity biotech feels like crypto in 2012, what the “GLP1 of aging” might be, and the ethical questions that come with reshaping how long humans can live.
📌 What You’ll Learn in This Episode:
Why longevity biotech is at the same stage today as crypto was a decade ago
How cell therapy and gene therapy are already reversing disease and extending healthspan
The science of epigenetic reprogramming and Yamanaka factors
Why cloning without consciousness could unlock unlimited organ replacement
The rise of embryo selection and what it means for the future of humanity
The coming GLP1 moment for longevity drugs
How AI and superintelligence will accelerate biotech breakthroughs
The demographic crisis of aging populations and how biotech can solve it
The ethical questions around immortality, consciousness, and equity of access
What Sebastian and Will believe the world could look like by 2040
⏱ Timestamps
0:00 Should we extend human lifespan?
0:28 Introducing Sebastian Brunemeier & Will Harborne
1:39 Why invest in longevity biotech now
5:25 What counts as longevity biotech?
7:11 Are we too early for radical life extension?
10:04 Gene therapy, stem cells and real-world examples
14:25 Germline immortality explained
18:40 Gene delivery, viral vs non-viral vectors
22:16 Replacement and cloning for organ growth
29:38 What does it mean to be human?
32:42 Embryo selection, polygenic scoring and ethics
42:40 Whole brain emulation and mind uploading
50:11 The low hanging fruit longevity drugs
57:00 What will be the GLP1 of longevity
1:04:03 How AI and superintelligence accelerate biotech
1:06:17 The silver tsunami and economic impact
1:13:05 Biological superintelligence and Homo Deus
1:18:10 Will longevity tech only be for the rich
1:21:59 Why small biotech will disrupt big pharma
1:22:15 Advice for founders and investors entering longevity
🎙 Hosted by Julian Issa
📸 Instagram: @thebeyondtomorrowpodcast
🌐 Website: www.beyondtomorrowpodcast.com
📩 Email: [email protected]
🎧 Subscribe on Spotify, Apple, and YouTube for more stories from the edge of what’s possible.
47 epizódok
Megosztás
